Inhibition of cytokine-induced sh2 protein in nk cells
AssigneeThe Walter and Eliza Hall Institute of Medical Research
InventorsNicholas D. Huntington, Sandra E. Nicholson, Jeff Babon, Tatiana Kolesnik
Life of this patent
Estimating the term…
Abstract
The present invention relates to therapeutic and prophylactic methods based on inhibition of CIS in NK cells. In particular, the present invention relates to treating or preventing a NK-responsive condition by administering to a subject a CIS inhibitor, or administering CIS-inhibited NK cells. The invention further relates to methods for identifying a CIS inhibitor, and for determining a likelihood of cancer response to treatment with CIS inhibition
Claims21
1-64. (canceled)
A method for adoptive cell therapy or prophylaxis comprising administering CIS-inhibited NK cells or CIS-inhibited T cells to a subject suffering from or determined to be at risk of suffering from a cancer or an infection.
Dependencies are inferred from the claim text.